Organovo (NASDAQ:ONVO) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO) in a research note published on Monday morning. The brokerage issued a sell rating on the medical research company’s stock.

Organovo Stock Down 11.3 %

ONVO stock opened at $0.54 on Monday. Organovo has a twelve month low of $0.32 and a twelve month high of $1.83. The stock has a market cap of $9.25 million, a P/E ratio of -0.63 and a beta of 0.44. The business’s 50-day moving average price is $0.43 and its 200-day moving average price is $0.45.

Organovo (NASDAQ:ONVO) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.05 million. On average, equities research analysts expect that Organovo will post -0.77 earnings per share for the current fiscal year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.